MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$192,399K
Net Income
$4,653K
Net Profit Margin
2.42%
EPS
$0.12
Unit: Thousand (K) dollars
Revenue Breakdown
EXPAREL
ZILRETTA
Iovera
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
192,399
177,376
196,873
179,516
Cost of goods sold (exclusive of amortization of acquired intangible assets)
44,164
36,413
40,299
34,278
Research and development
30,243
28,072
37,804
25,966
Selling, general and administrative
91,809
93,944
101,608
91,797
Amortization of acquired intangible assets
14,322
14,322
14,322
14,322
Goodwill impairment
-
-
0
0
Contingent consideration gains, acquisition-related expenses, restructuring and other
-
-
500
6,791
Other operating expenses, net
-7,594
2,277
-
-
Total operating expenses
188,132
170,474
194,533
173,154
Income from operations
4,267
6,902
2,340
6,362
Interest income
1,944
1,930
2,295
8,534
Interest expense
3,622
3,699
3,892
4,279
(gain) loss on early extinguishment of debt
-
-
0
-983
Other, net
-34
-135
-172
-110
Total other expense, net
-1,712
-1,904
-1,769
3,162
Income (loss) before income taxes
2,555
4,998
571
9,524
Income tax benefit (expense)
-2,098
2,082
-1,066
4,092
Net income (loss)
4,653
2,916
1,637
5,432
Basic EPS
0.12
0.07
0.039
0.12
Diluted EPS
0.12
0.07
0.037
0.12
Basic Average Shares
39,462,000
40,461,000
42,492,000
44,038,000
Diluted Average Shares
40,300,000
40,910,000
43,724,000
44,459,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
EXPAREL
$147,823K
ZILRETTA
$32,648K
Iovera
$6,806K
Bupivacaine Liposome
Injectable Suspension
$3,216K
Product
$190,493K
(5.63%↑ Y/Y)
Royalty
$1,906K
(153.46%↑ Y/Y)
Total revenues
$192,399K
(6.24%↑ Y/Y)
Income from operations
$4,267K
(-49.79%↓ Y/Y)
Total operating
expenses
$188,132K
(9.00%↑ Y/Y)
Income (loss) before
income taxes
$2,555K
(232.59%↑ Y/Y)
Income tax benefit
(expense)
-$2,098K
(-171.85%↓ Y/Y)
Total other expense,
net
-$1,712K
(83.58%↑ Y/Y)
Interest income
$1,944K
(-61.18%↓ Y/Y)
Selling, general and
administrative
$91,809K
(3.65%↑ Y/Y)
Cost of goods sold
(exclusive of amortization...
$44,164K
(8.07%↑ Y/Y)
Research and development
$30,243K
(7.24%↑ Y/Y)
Amortization of acquired
intangible assets
$14,322K
(0.00%↑ Y/Y)
Other operating
expenses, net
-$7,594K
Net income (loss)
$4,653K
(196.00%↑ Y/Y)
Interest expense
$3,622K
(-22.85%↓ Y/Y)
Other, net
-$34K
(99.68%↑ Y/Y)
Buy us a coffee
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)